- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:59 | NICE aims to cut funding for Amgen lung cancer drug Lumykras | 5 | pharmaphorum | ||
| Di | How Safe Is Amgen's Dividend? | 11 | The Motley Fool | ||
| Di | If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today | 4 | Benzinga.com | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| Mo | Amgen issues recall for close to 1M heart med bottles due to contamination | 10 | FiercePharma | ||
| 02.07. | With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs | 21 | MedCity News | ||
| 02.07. | Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS | 24 | FierceBiotech | ||
| 02.07. | Roche lung cancer therapy beats rivals from Amgen, BMS in late-stage trial | 8 | Seeking Alpha | ||
| 01.07. | Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel | 3 | Reuters | ||
| 01.07. | BMO Capital maintains Amgen stock rating citing Tavneos concerns | 5 | Investing.com | ||
| 30.06. | Viridian may have edge over Amgen in eye drug showdown, analysts argue | 4 | BioPharma Dive | ||
| 30.06. | Medical journal retracts Tavneos pivotal study article, complicating Amgen's defense effort | 3 | FiercePharma | ||
| 29.06. | FDA rejects Sobi's gout drug over manufacturing issues, sparing Amgen blockbuster | 27 | FiercePharma | ||
| 29.06. | Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease | 5 | Benzinga.com | ||
| 29.06. | Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa | 3 | FiercePharma | ||
| 28.06. | FDA Approves Viridian's Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med | 12 | MedCity News | ||
| 26.06. | Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms | 10 | FiercePharma | ||
| 26.06. | Amgen faces EU withdrawal of rare-disorder therapy Tavneos | 23 | Seeking Alpha | ||
| 26.06. | Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential | 11 | Insider Monkey | ||
| 26.06. | Amgen - AMGN: Pharma-Aktie mit Cup & Handle! | 793 | ratgeberGELD.at | Fliegt der Deckel bald weg? Kursziel Allzeithoch! Amgen (AMGN) erhöht Dividenden seit 2011! Dividendenrendite 2025: 2.91 Prozent! Amgen (AMGN) - US0311621009 Rückblick: Bei dem schwachen US-Gesamtmarkt... ► Artikel lesen | |
| 16.06. | MariTide-Ausblick: Mizuho hebt Amgen-Kursziel auf 303 US-Dollar an | 28 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
294 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VIRAX BIOLABS GROUP | 9,250 | +190,88 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,820 | +2,13 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,37 | +0,09 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| ABSCI | 11,395 | +2,66 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 62,31 | -8,00 % | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | ||
| BEAM THERAPEUTICS | 36,070 | -2,20 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,130 | -0,71 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ERASCA | 19,530 | +3,50 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 47,090 | +1,71 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| RECURSION PHARMACEUTICALS | 3,805 | +2,28 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,670 | +0,60 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| ALUMIS | 30,240 | +1,68 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD | ||
| CG ONCOLOGY | 73,24 | +4,92 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,205 | +2,93 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein |
Das Unternehmen AMGEN INC CDR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+0,60 %) liegt der Kurs bei 16,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.